Immunic AG
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: IMU-838 tabletsDrug: Placebo matching IMU-838 tablets
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 1050
- Registration Number
- NCT05201638
- Locations
- 🇹🇷
T.C. Ministry of Health Kutahya Provincial Directorate of Health Kutahya University of Health Sciences Evliya Celebi Training and Research Hospital, Kütahya, Turkey
🇵🇱Centrum Med. Ibismed, Zabrze, Poland
🇷🇸Vojnomedicinska akademija, Belgrade, Serbia
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: IMU-838 tabletsDrug: Placebo matching IMU-838 tablets
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 1050
- Registration Number
- NCT05134441
- Locations
- 🇺🇸
Xenoscience, Inc., 21st Century Neurology, Phoenix, Arizona, United States
🇺🇸Bradenton Research Center, Bradenton, Florida, United States
🇦🇱Hygeia Hospital Tirana, Tirana, Albania
IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Drug: IMU-935
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 18
- Registration Number
- NCT05124795
- Locations
- 🇬🇧
Institute of Cancer Research, London, United Kingdom
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: IMU-838Drug: Placebo matching IMU-838
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 450
- Registration Number
- NCT05054140
- Locations
- 🇧🇬
Dr. Penko Shotekov, Sofia, Bulgaria
🇧🇬UMHAT Alexandrovska, Sofia, Bulgaria
🇳🇱Dr. Eva Strijibis, Amsterdam, Netherlands
A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
- Conditions
- COVID-19
- Interventions
- Drug: IMU-838Other: Placebo
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 234
- Registration Number
- NCT04379271
- Locations
- 🇧🇬
Military Medical Academy, Clinic of Infectious Diseases, Sofia, Bulgaria
🇧🇬UMHATEM N.I.Pirogov, Clinic of internal diseases, Sofia, Bulgaria
🇩🇪University Hospital Frankfurt, Infectious Diseases, Frankfurt, Germany
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
- Conditions
- Relapsing-Remitting Multiple Sclerosis (RRMS)
- Interventions
- Drug: IMU-838 (30 mg/day)Drug: IMU-838 (45 mg/day)Drug: PlaceboDrug: IMU-838 (10 mg/day)
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 210
- Registration Number
- NCT03846219
- Locations
- 🇧🇬
MHAT Pulse AD, Department of Neurology Diseases, Blagoevgrad, Bulgaria
🇧🇬UMHAT " Kaspela" EOOD, Department of Neurology Diseases, Plovdiv, Bulgaria
🇧🇬UMHAT "Kanev Ruse", Department of General and Vascular Neurology, Ruse, Bulgaria
Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: IMU-838Drug: Placebo
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 263
- Registration Number
- NCT03341962
- Locations
- 🇲🇰
University Clinic for Hematology - Skopje - Macedonian Hematology Association, Skopje, North Macedonia
🇺🇸Alliance Medical Research, LLC, Lighthouse Point, Florida, United States
🇺🇸Del Sol Research Management, LLC, Tucson, Arizona, United States